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The human gut microbiome is involved in vital biological
functions such as maintenance of immune homeostasis,
modulation of intestinal development and enhanced meta-
bolic capabilities. Disturbances of intestinal microbiota have
been associated with development and progression of in-
ﬂammatory conditions including GVHD. Non-secretor in-
dividuals do not express the H antigen on mucosal surfaces
and body ﬂuids due to a homozygous single nucleotide
polymorphism in the fucosyltransferase 2 (FUT2) gene
(428G>A) and FUT2 genotype has been shown to modify the
gut microbiome. We hypothesized that FUT2 genotype in-
ﬂuences risk of GVHD and bacterial translocation following
allogeneic HSCT.
FUT2 genotype was determined in 150 consecutive patients
receiving allogeneic HSCT at our center. We abstracted clin-
ical characteristics and outcomes from the transplant
database.
Median age at transplantationwas 6.31 years andmale/female
ratio was 97/53. Genetic analysis revealed 23% recipients had
A/A genotype (n¼34), 52% A/G genotype (n¼78) and 25% G/G
genotype (n¼38); Hardy Weinberg equilibrium was con-
ﬁrmed. Hematologicmalignancies comprised 30% (n¼45), 29%
immune deﬁciencies (n¼43), 22% bonemarrow failure (n¼33),
12% hemophagocytic lymphohistiocytosis (HLH) (n¼18), 4%
metabolic diseases (n¼6), 3% hemoglobinopathies (n¼4), and
one patient with Evan’s syndrome. 54% receivedmyeloablative
conditioning (n¼81), while 46% received reduced intensity
conditioning (n¼68). Stem cell source was bone marrow in
81% (n¼122), peripheral blood stem cells in 11% (n¼16), cord
blood in 7% (n¼11), and one patient received both bone
marrow and cord blood from a sibling donor. Among donors,29% were matched sibling donors (n¼43), 49% matched un-
related or other family member donors (n¼74) and 22% were
mismatched donors (n¼33). Acute GVHD occurred in 36% of
patients (n¼54). Cumulative risk of any acute GVHD varied by
FUT2 genotypewith decreased risk in thosewith A/A genotype
and increased risk in those with G/G genotype (p¼0.04) (Fig.
1). A/A genotype (OR¼0.4 p-value¼0.046), myeloablation
(OR¼1.99 p-value¼0.029) and matched sibling donor
(OR¼0.41 p-value¼0.026) were identiﬁed to be signiﬁcant
GVHD risk factors in multivariate analysis. Bacteremia
occurred in 34% of patients (n¼51), and in contrast to our
ﬁndings in GVHD cumulative incidence was increased in A/A
genotype (p-value¼0.01) (Fig. 1). A/A genotype (OR¼3.94 p-
value¼0.0047) and A/G genotype (OR¼2.46 p-value¼0.05)
were associated with increased risk in multivariate analysis.
FUT2 genotype inﬂuences risk of acute GVHD and bacteremia
following HSCT. We hypothesize that the mechanism in-
volves altered composition and diversity of gut microbiome,
and limited data indicate increased diversity of the gut
microbiome in the A/A genotype, but this requires additional
studies.105
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Introduction: AutoHCT is a potentially curative modality for
Rel/Ref HL. However, large studies evaluating the risk factors
predicting outcomes of autoHCT in CAYA with Rel/Ref HL
have not been performed.
Figure. Overall Survival in HSCT Patients Deﬁcient in Vitamin D. Survival
curves for patients deﬁcient in Vitamin D at 100 days after HSCT was calcu-
lated using Kaplan-Meier and the Log Rank test. Patients with severe Vitamin
D deﬁciency (Serum 25-hydroxy(25-OH) vitamin D levels 20 ng/ml, n¼40)
had signiﬁcantly worse overall survival than those with Vitamin D level
>20ng/mL (n¼89)(p¼0.044).
Baseline characteristics N¼671 (%)
Median age (range) 23 (3-29)
<21 yrs 230 (34)
KPS 90 498 (74)
Duration of 1st CR
<12mons (including primary refractory) 361 (54)
12mons 237 (35)
Missing 73 (11)
Time from diagnosis to HCT, mons (range) 19 (3-238)
High LDH at HCT 174 (26)
Median lines of therapies (range) 2 (1-5)
ABVD or ABVD-like 1st line therapy 396 (59)
END at HCT 118 (18)
Bulky disease at HCT 77 (11)
Disease status at HCT
Sensitive 529 (79)
Resistant 125 (19)
Missing 17 (3)
Radiation post HCT 205 (31)
Conditioning
BEAM 455 (68)
CBV 80 (12)
Others 136 (20)
Graft type
BM 65 (10)
PB 606 (90)
Median follow-up, mons (range) 64 (4-216)
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dergoing autoHCT during 1995-2010 were eligible. HIV+
patients and those undergoing tandem HCT were excluded.
Results: Baseline characteristics of 671 CAYA included in the
analysis are shown in Table. The 3yr non-relapse mortality
(NRM), rate of relapse/progression (R/P), progression free sur-
vival (PFS) and overall survival (OS)were 6%, 38%, 56% and73%,
respectively. On multivariate analysis non-ABVD/ABVD-like
1st line therapy (RR 1.8; p¼0.03) was associated with a higher
NRM. Factors predicting higher risk of R/P included Lansky
score (LS) or KPS<90 (RR 1.6; p¼0.0006), extranodal disease
(END) (RR 1.6; p¼0.001), resistant disease (RR 1.8; p<0.0001)
and CBV conditioning (RR 1.6; p¼0.002). Long ﬁrst complete
remission (LgCR1; 1yr) was associated with a reduced R/P
risk (RR 0.6; p¼0.003). MVA for PFS identiﬁed END (RR 1.5;
p¼0.001), resistant disease (RR 1.9; p<0.0001) and KPS<90
(RR 1.5; p¼0.0004) as risk factors for therapy failure; while
LgCR1 (0.7; p¼0.006)waspredictive of reduced therapy failure
risk. Finally for OS, non-ABVD/ABVD-like 1st line therapy (RR
1.5; p¼0.001), END (RR 1.7; p¼.0003) and resistant disease (RR
2.3; p<0.0001) were associated with higher mortality; while
LgCR1 (RR 0.5; p¼0.0006) and peripheral blood graft (RR 0.49,
p¼0.0001) were associated with reduced mortality risk. Age
was not predictive of autoHCT outcomes.
Conclusions: Unlike adult HL patients, age is not a prog-
nostic factor for CAYA outcomes following autoHCT. In this
largest CAYA study to date, LgCR1, LS/KPS, chemoresistance,
END and non-ABVD/ABVD-like 1st line therapy emerge as
factors predicting autoHCT survival outcomes in CAYA with
HL. These data help identify potential high-risk Rel/Ref CAYA
with HL, where investigation of novel post autoHCT (main-
tenance, consolidation, immunomodulatory etc.) approaches
are warranted.
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Pre-Hematopoietic Stem Cell Transplantation Lung
Function and Pulmonary Complications in Children
Ashok Srinivasan 1, Saumini Srinivasan 2,
Sudeep Sunthankar 3, Anusha Sunkara 4, Guolian Kang 5,
Dennis Stokes 6, Wing Leung 7. 1 Bone Marrow Transplantation
and Cellular Therapy, St. Jude Children’s Research Hospital,
Memphis, TN; 2 Department of Pediatrics, Division ofPulmonology, Memphis, TN; 3Medical University of South
Carolina, Charleston, SC; 4 Biostatistics, St. Jude Children’s
Research Hospital, Memphis, TN; 5 Biostatistics, St. Jude
Children’s Research Hospital, Memphis, TN; 6 Division of
Pulmonology, University of Tennessee Health Science Center,
Memphis, TN; 7 Bone Marrow Transplantation and Cellular
Therapy, St. Jude Children’s Research Hospital, Memphis, TN
Rationale: Pulmonary complications are a signiﬁcant cause
of morbidity and mortality after allogeneic hematopoietic
stem cell transplantation.
Objectives: The relationship between pre-transplant pul-
monary function tests (PFT) and development of post-
transplant pulmonary complications in childrenwas studied.
Methods: This is a retrospective single institution cohort
study of 410 patients who underwent pre-transplant PFT and
were followed up to 10 years post-transplant.
Results: Pulmonary complications were observed in 174
(42%) patients. Children with pulmonary complications had
signiﬁcantly lower FEF25-75% (P ¼ 0.02) derived using con-
ventional predicted equations for age, and the Global Lung
Initiative-2012 predicted equations (P ¼ 0.01). T-cell deple-
tion (P ¼ 0.001), acute grade 3-4 graft-versus-host disease
(GVHD; P ¼ 0.008), and chronic GVHD (P ¼ 0.01) increased
risk for pulmonary complications. Patients who had pulmo-
nary complications had a 2.8-fold increased risk of mortality
(P < 0.0001). The cumulative incidence of death due to
pulmonary complications was signiﬁcantly higher in chil-
drenwho had low lung volumes, functional residual capacity
(FRC) < 50% (P ¼ 0.005), total lung capacity (TLC) < 50% (P ¼
0.0002), residual volume (RV) < 50% (P ¼ 0.007), and T-cell
depletion (P ¼ 0.01). Lower forced expiratory volume in one
second (FEV1; P ¼ 0.0005), forced vital capacity (FVC; P ¼
0.0005), TLC (P< 0.0001), RV< 50% (P¼ 0.01), and restrictive
lung disease (RLD; P¼ 0.01) predicted worse overall survival.
Conclusions: Abnormal pre-transplant PFT signiﬁcantly
increased risk post-transplant. These patients may beneﬁt
from modiﬁed transplant strategies to reduce morbidity and
mortality.
